Investigational New Drugs Oerlemans, R, Berkers, C R, Assaraf, Y G, Scheffer, G L, Peters, G J, Verbrugge, S E, Cloos, J, Slootstra, J, Meloen, R H, Shoemaker, R H, Dijkmans, B A C, Scheper, R J, Ovaa, H & Jansen, G 2018, ' Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide ', Investigational New Drugs, vol. 36, no. 5, pp. 797-809 . https://doi.org/10.1007/s10637-018-0569-x Investigational New Drugs, 36(5), 797-809. Kluwer Academic Publishers Investigational New Drugs, 36(5), 797-809
Journal of Molecular and Clinical Medicine, 1(1):DOI: 10.31083/j.jmcm.2018.01.005, 37-46 van de Ven, R, Verbrugge, S E, Al, M, Dekker, H, Verheul, HMW, Anderl, J L, Chan, E T, Dijkmans, BAC, Lems, WF, Scheper, RJ, Jansen, G & de Gruijl, TD 2018, ' Enhanced Dendritic Cell Development Through Long-Term Proteasome Inhibition ', Journal of Molecular and Clinical Medicine, vol. 1, no. 1, DOI: 10.31083/j.jmcm.2018.01.005, pp. 37-46 .
Amino Acids, 46(4), 793-808. Springer Wien Hitzerd, S M, Verbrugge, C S E, Ossenkoppele, G J, Jansen, G & Peters, G J 2014, ' Positioning of aminopeptidase inhibitors in next generation cancer therapy ', Amino Acids, vol. 46, no. 4, pp. 793-808 . https://doi.org/10.1007/s00726-013-1648-0
Oncotarget, 7(5), 5240-5257. Impact Journals Verbrugge, C, Al, M, Assaraf, Y G, Kammerer, S, Chandrupatla, D M S H, Honeywell, R J, Musters, R P J, Giovannetti, E, O'Toole, T, Scheffer, G L, Krige, D, de Gruijl, T D, Niessen, J, Lems, W F, Kramer, P A, Scheper, R J, Cloos, J, Ossenkoppele, G J, Peters, G J & Jansen, G 2016, ' Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR ', Oncotarget, vol. 7, no. 5, pp. 5240-5257 . Oncotarget
Cillessen, S A G M, Hijmernig, N J, Moesbergen, L M, Vos, W, Verbrugge, C S E, Jansen, G, Visser, O J, Oudejans, J J & Meijer, C J L M 2015, ' ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2 ', Haematologica, vol. 100, no. 9, pp. E365-E368 . https://doi.org/10.3324/haematol.2014.118828 Haematologica, 100(9), e365. Ferrata Storti Foundation Haematologica, 100(9), E365-E368. Ferrata Storti Foundation
Verbrugge, C S E, Scheper, R J, Lems, W F, de Gruijl, T D & Jansen, G 2015, ' Proteasome inhibitors as experimental therapeutics of autoimmune diseases ', Arthritis Research & Therapy, vol. 17, 17 . https://doi.org/10.1186/s13075-015-0529-1 Arthritis Research & Therapy, 17:17. BioMed Central Arthritis Research & Therapy Arthritis Research & Therapy, 17. BioMed Central
Verbrugge, C S E, Al, M C M, Assaraf, Y G, Niewerth, D, van Meerloo, J, Cloos, J, van der Veer, M S, Scheffer, G L, Peters, G J, Chan, E T, Anderl, J L, Kirk, C J, Zweegman, S, Dijkmans, B A C, Lems, W F, Scheper, R J, de Gruijl, T D & Jansen, G 2013, ' Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors ', Experimental hematology & oncology, vol. 2, 2 . https://doi.org/10.1186/s40164-016-0032-7 Experimental hematology & oncology, 2:2. BioMed Central Experimental Hematology & Oncology Experimental Hematology & Oncology, Vol 2, Iss 1, p 2 (2013) Experimental hematology & oncology, 2(1), 2-12. BioMed Central Verbrugge, S E, Al, M, Assaraf, Y G, Niewerth, D, Meerloo, J V, Cloos, J, Veer, M V D, Scheffer, G L, Peters, G J, Chan, E T, Anderl, J L, Kirk, C J, Zweegman, S, Dijkmans, B A C, Lems, W F, Scheper, R J, Gruijl, T D D & Jansen, G 2013, ' Overcoming bortezomib resistance in human B cells by anti-CD20 / rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors ', Experimental hematology & oncology, vol. 2, no. 1, pp. 2-12 . https://doi.org/10.1186/2162-3619-2-2